Clinical Outcomes Improve with Highly Active Antiretroviral Therapy in Vertically HIV Type‐1–Infected Children
Authors:
- Salvador ResinoSRSalvador Resino
- Rosa ResinoRRRosa Resino
- Jose Ma BellonJBJose Ma Bellon
- Ma Angeles Munoz‐FernandezMMMa Angeles Munoz‐Fernandez
- Spanish Group of Pediatric HIV InfectionSISpanish Group of Pediatric HIV Infection
Open Access
- 15 July 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (2) , 243-252
Abstract
Background. Use of antiretroviral therapy has resulted in a decrease in morbidity and mortality rates in human immunodeficiency virus type 1 (HIV-1)—infected children. Methods. We performed a retrospective study involving 427 children to determine the effectiveness of different antiretroviral therapy protocols on clinical outcome. The follow-up period was divided into 5 calendar periods (CPs): CP1 (1980–1989), before antiretroviral therapy was administered; CP2 (1990–1993), when monotherapy was administered; CP3 (1994–1996), when combined therapy was administered; CP4 (1997–1998), when ⩽50% of children were receiving highly active antiretroviral therapy (HAART); and CP5 (1999–2003), when ⩾60% of children were receiving HAART. Results. Children experienced a progressive increase in the CD4+ cell count and decrease in the viral load from 1997 onwards. A lower number of AIDS cases and deaths occurred during CP5 than during the other CPs (P < .01), with a relative risk of an absence of AIDS of >20 and a relative risk of survival of >30. The AIDS rate was >50% in CP1; we observed a very strong decrease to 14% in CP2, to 16% in CP3, to 7% in CP4, and to 2% in CP5. The mortality rates in CP2 and CP3 were >6% and thereafter decreased to 0.5% in CP5. The relative risks for no hospital admission in CP4 and CP5 were >3.5. The total rates of hospital admission in CP1, CP2, and CP3 were >30%; we observed a decrease in CP4 and CP5. The duration of hospitalization decreased during the follow-up period, and it was higher in CP1 (∼30 days) than in the other periods. Conclusions. We observed that HAART produces a decrease in adverse clinical outcomes (i.e., hospital admission, AIDS, and death) in children with vertical HIV-1 infection in Madrid, Spain.Keywords
This publication has 31 references indexed in Scilit:
- Temporal Trends in Early Clinical Manifestations of Perinatal HIV Infection in a Population-Based CohortJAMA, 2005
- Sustained Viral Suppression and Immune Recovery in HIV Type 1--Infected Children after 4 Years of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2005
- Protease Inhibitor Combination Therapy, Severity of Illness, and Quality of Life Among Children With Perinatally Acquired HIV-1 InfectionPediatrics, 2005
- Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1New England Journal of Medicine, 2001
- Antiretroviral Therapy and Mortality Among Children With Perinatal HIV InfectionJAMA, 2000
- Reduction in Mortality With Availability of Antiretroviral Therapy for Children With Perinatal HIV-1 InfectionJAMA, 2000
- Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1New England Journal of Medicine, 1999
- Treatment of Human Immunodeficiency Virus 1‐Infected Infants and Children with the Protease Inhibitor Nelfinavir MesylateClinical Infectious Diseases, 1999
- Prognostic significance of immunologic changes in 675 infants perinatally exposed to human immunodeficiency virusThe Journal of Pediatrics, 1991
- Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV InfectionNew England Journal of Medicine, 1988